2 completed, 1 not yet recruiting, 1 recruiting, 1 unknown. 4 Phase 1, 3 Phase 2.
By phase and status
Follow Gammopathy, Monoclonal: new trials by email Literature Review of Gammopathy, Monoclonal trials Research Report on Gammopathy, Monoclonal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
Belantamab Mafodotin-Blmf, Lenalidomide, Dexamethasone - Multiple Myeloma, Neoplasms | Phase 1 / Phase 2 | Recruiting | 36 | 2023-07-14 | 2023-10-24 |
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
Belantamab Mafodotin-Blmf, Daratumumab, Pomalidomide - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 / Phase 2 | Not yet recruiting | 48 | 2022-10-20 | 2022-10-17 |
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
Belantamab Mafodotin-Blmf, Daratumumab, Lenalidomide - Multiple Myeloma, Neoplasms | Phase 1 / Phase 2 | Unknown | 36 | 2022-04-13 | 2023-12-01 |
Monoclonal Gammopathy With Clinical Significance in Patients With and Without Haematological Malignancies in Finistère Between 2012 and 2017 (GammaClinik)
Gammopathy, Monoclonal | | Completed | 80 | 2021-10-01 | 2024-08-19 |
Rifaximin in Patients With Monoclonal Gammopathy
Rifaximin - IgA Monoclonal Gammopathy, IgG Monoclonal Gammopathy | Phase 1 | Completed | 50 | 2019-05-15 | 2026-05-26 |
Narrower conditions
Paraproteinemias (5) · Blood Protein Disorders (3) · Corneal Diseases (3) · Hematologic Diseases (3) · Multiple Myeloma (3) · Neoplasms (3) · Neoplasms, Plasma Cell (3) · Waldenstrom Macroglobulinemia (1)
Broader conditions
Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Cardiovascular Diseases (4) · Hemorrhagic Disorders (4) · Hemostatic Disorders (4) · Lymphoproliferative Disorders (4) · Neoplasms by Histologic Type (4) · Vascular Diseases (4) · Eye Diseases (3) · Blood Protein Disorders (2) · Hematologic Diseases (2) · Lymphatic Diseases (1) · Neoplasms (1) · Neoplasms, Plasma Cell (1)
Interventions
Dexamethasone (3) · Lenalidomide (2) · daratumumab (2) · Rifaximin (1) · nirogacestat (1) · pomalidomide (1)
Sponsors
Hellenic Society of Hematology (3) · Emory University (1) · University Hospital, Brest (1)
Countries
Greece (2) · France (1) · United States (1)
Top investigators
Evangelos Terpos, Prof (3) · Ajay Nooka, MD (1)
NIH funding
P30CA138292 (1)